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ABSTRACT

Published articles constitute a huge repository of population pharmacokinetic (Pop
PK) models that can be repurposed to answer dose-related questions. We present a
Simulation-Informed-Statistically-Aided (SISA) method that can be used to select
population pharmacokinetic models from literature for repurposing.
Seven published melphalan PK models, and 1 reference model from FDA NDA
submission documents were selected. A 30 minute IV infusion of 140 mg/m2 of
melphalan was simulated using each of the 7 models. The predictive performance of
each of the models were evaluated using a proposed method called modified standard
normal deviate (mSND). Five models, M1, M3, M4, M5 and M6 performed well
predicting the given dose with mSND within 0 -3. A composite dataset was generated
from these 5 models and used to develop a composite melphalan PK model using Firstorder conditional estimation method with interaction (FOCE-I), and the Bayesian
Hamiltonian Monte Carlo No-U-Turn Sampler (HMC NUTS) estimation methods. Both
informative and weakly informative priors were tested during the Bayesian estimation.
For both Bayesian and Non-Bayesian methods, a two compartmental model
adequately fit the composite data. The parameter estimates and the model predictions
were in agreement with those from reference model. This confirmed that validity of
SISA. Again, the findings suggested that literature data can be repurposed to develop
composite PK models.
It is hoped that further refinement of this method will provide a more objective
approach for selecting PK models for repurposing.
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CHAPTER 1

1

1.1

INTRODUCTION

Published articles constitute a huge repository of PK models

Published articles constitute a huge repository of population pharmacokinetic (Pop
PK) models (Chen et al., 2018, Tsamandouras et al., 2017, Snelder et al., 2019, Xue et
al., 2011, Nath et al., 2010, Lamba et al., 2010). This provides researchers with a ready
and inexpensive source of models to answer dose-related questions, before further
investigations in humans. Selection of Pop PK models from literature could however be
challenging when you have multiple models to choose from. Direct comparison of the
model parameters and study design alone do not offer an objective approach for
selection. There is therefore the need to develop an approach that incorporates the model
parameters and study design, and apply statistical methods to compare predictions of
exposure after a single dose.
In this work, we present a simulation-informed statistically-aided (SISA) method
that can be used to select population pharmacokinetic models from literature for
repurposing.
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1.2

Pharmacokinetic modeling and simulation (M&S) are important tools for drug
development.

The cost of drug development is huge, about 1 – 3 billion dollars (DiMasi et al.,
2016), and companies are pursuing various strategies to minimize it. Modeling and
simulation is gaining a wide acceptance in drug development due to its potential to
reduce the cost of drug development. With a single model, thousands of simulations
may be performed in silico before actual experiments in animals or man. In addition to
cost reduction, this approach reduces the number of participants and experiments to be
conducted.
Pharmacokinetic modeling and simulation (M&S) is a powerful tool used by
clinical pharmacologist to characterize the time course of drugs, and also to predict
doses. Several clinical questions regarding dose and administration of drugs have been
answered with simulations and confirmed with actual studies (Aarons et al., 2001).
Considering the number of PK models in literature, it may be prudent to repurpose
published PK models than to develop new ones from the scratch. However, the selection
of the model requires the consideration of multiple factors.
Firstly, there is the need to compare the subject population from which the PK
model was developed. This may include gender, race, diseases, etc. Second, one may
have to compare the design of the pharmacokinetic studies, and lastly the parameters
from each model. This process is not easy to perform without a well-defined procedures.
To date, only an empirical approach is used. This approach uses the number of
citations, relevance of population, or author reputation as criteria for selection of
population PK models from literature. Whereas this is straight forward, it is biased and
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might miss the opportunity of selecting the best model for use. A more objective criteria
that combines study design and PK parameters would greatly enhance PK selection.

1.3

Melphalan pharmacokinetic model in literature

Melphalan was chosen for the purposes of this study because of the availability of
multiple models in literature. It is an alkylating chemotherapeutic agent, and
increasingly, it is gaining more acceptance as an important agent for the treatment of
multiple myeloma (Martino et al., 2013, Kuhne et al., 2008, Mateos et al., 2015). This
is due to its myeloablative effect, and availability in both oral (ALKERAN®) and
intravenous (EVOMELA®) dosage forms.

1.4

Overall goal of this project

The overall objectives of this thesis are to:
1. Identify population pharmacokinetic models that characterize the disposition of
melphalan in patients from literature.
2. Develop a criterion to guide the selection of melphalan models from literature.
3. Generate composite melphalan pharmacokinetic data from literature through
simulation.
4. Develop composite population PK model for melphalan using Bayesian and
non-Bayesian estimation methods.

3

CHAPTER 2

2

REVIEW OF LITERATURE

2.1

PHARMACOKINETIC CONCEPTS

2.1.1

Pharmacokinetics and the disposition of drugs

Pharmacokinetics is a term used in pharmacology to describe the processes of
absorption (A), distribution (D), metabolism (M) and excretion (E). After oral or
subcutaneous administration of a drug, it is absorbed into circulation, and may interact
with blood components like albumin (Yamasaki et al., 2013). The remainder of the drug
molecules unbounded to blood components move into different body compartments,
either passively by diffusion, or actively by transporters.
The fate of the drug in different body compartments is determined by the
availability of enzymes (e.g. Cytochrome P450) (Guengerich, 1992), transporters (e.g.
p-glycoprotein) (Nigam, 2015), and other physiological factors. The enzymes mediate
the metabolism of the drug into a more soluble form. Both metabolized and parent drugs
may be excreted from the body via the renal or biliary routes.
The skin and the gastrointestinal tract are the major sites of drug absorption after
subcutaneous or oral administration respectively. The liver expresses many enzymes for
metabolism, making it one of the most important sites for drug metabolism. The bile
and kidney serve as key organs for the excretion of drugs from the body.
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Quantitatively, absorption is described by the absorption rate constant (ka) and the
bioavailability fraction (F). The absorption rate constant describes the speed of
absorption, whereas the bioavailability factor describes the extent to which an oral or
subcutaneous dose is available to systemic circulation relative to intravenous
administration. Similarly, distribution is described by the volume of distribution
parameter (V), and elimination by the clearance parameter (Cl ).

2.1.2

Population Pharmacokinetic (Pop PK) models

Population pharmacokinetic models describe the time course of drugs in the body.
They provide mathematical and statistical description of the absorption (A), distribution
(D), metabolism (M) and excretion (E) of drugs (Van Der Graaf and Gabrielsson, 2009).
Pop PK models support the determination of doses for clinical trials, and provide a
framework for evaluating factors that can influence the ADME processes. Figure 1
summarizes areas where pharmacokinetic modeling and simulations are commonly used
in drug development (Mould and Upton, 2012).

5

Figure 1. Modeling and simulation during drug development. Diagram was obtained
from (Mould and Upton, 2012).

2.1.3

Pop PK models are non-linear mixed effects compartmental models.

Population pharmacokinetic models are non-linear mixed effect models (Van Der
Graaf and Gabrielsson, 2009, Aarons et al., 2001). They combine structural (fixed) and
stochastic (random) models to describe the disposition of drugs. The structure can be
one (Ren et al., 2019), two (Karatza and Karalis, 2019), or multi compartments (Asaumi
et al., 2019). The parameters in the structural model are known as fixed-effects, and are
relevant for the characterization of the absorption (ka and F), distribution (V), and
elimination (CL or Q). The stochastic model accounts for the magnitude, and the
sources of variability in the fixed-effect parameters. The parameters in the stochastic
part are known as random-effect.
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The two main types of random effects in population pharmacokinetic model are the
inter-individual variability (IIV) and the residual error variability. The IIV describes
differences between individuals which may be attributed to demographic, physiological
and biochemical differences. The residual error model on the hand accounts for the error
associated with the collection of the pharmacokinetic samples and potential
misspecification of the structural PK model.

2.1.4

Schematic presentation of Population pharmacokinetic models

Theoretical or imaginary compartments are used to illustrate pharmacokinetic
models in a simplified way. The organs and tissues of the body are represented by the
compartments. The number of compartments in a model depends on the assumptions
regarding the absorption, distribution and elimination of drug from the body. A
population pharmacokinetic model may thus be described as one-compartment, twocompartment or multi-compartment model.
A one compartmental model assumes that the distribution of drug is limited to only
a central compartment after administration. This central compartment represents all
tissues that are able to achieve rapid equilibration with the plasma drug concentration.
A two compartmental model on the other hand, has an additional peripheral
compartment that achieves equilibration a little later. Thus, there is a flux of drug
between the central and peripheral compartment as illustrated in Figure 2.

7

Figure 2. Schematic representation of one and two-compartmental models after IV and
oral administration.

2.1.5

Exposure measures

The exposure of a drug describes its concentration in circulation or at the site of
action over a defined period of time. It is important in pharmacokinetics to determine
the exposure levels that are relevant to achieve a therapeutic response to a drug. The
exposure measures commonly used to define the exposure levels are the Ctrough, Cmax,
Tmax, Tmin, and AUC.
Ctrough is the minimum quantifiable concentration of a drug measured at time
Tmin. Cmax, on the other hand, is the maximum concentration of a drug measured at
time Tmax. The AUC is the concentration under the concentration-time curve calculated
to determine the total concentration of a drug over a period of time. The AUC can be
8

estimated using non-compartmental analysis (NCA), whereas, the Ctrough, Tmin,
Cmax and Tmax can be determined directly from the concentration-time data.

9

2.2

STATISTICAL CONCEPTS

2.2.1

Mathematical presentation of population pharmacokinetic models

The mixed effect model (Drikvandi, 2017) can be represented by the following
equations:
y = f t ,φ ,D + ε
φ =φ

+ η

Where
ε = ~ iid N(0, σ )
η = ~ N(0, ω )

•

yi1, …, yij: j repeated measurements on the ith subject, where yij is the plasma
concentration for subject i measured at time tij.

•

f is a nonlinear function of time which depends on the φ and D. The function
can be a one, two, or multi-compartmental model.

•

D is the dose of drug administered

•

φi are individual parameters

•

φpop is a vector of population parameters

•

εij is the residual errors associated with plasma concentration measurements, yij

The nonlinear mixed effect model is the joint probability distribution of (y, φ):
( ,
( ,

#

; !) = " (
#

$%

; !) = " (
$%
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, ; !)

, ; !) ∗ ( ; !)

2.2.2

The population pharmacokinetic model of melphalan

The pharmacokinetic profile of melphalan was described by two-compartmental
model (Figure 2) and expressed by equations below:
The likelihood of melphalan parameters after a dose of D is infused at time Tinf is
expressed as:
0

L(CL, V1, Q, V2, σ |y1, . . , yn, t1, . . , tn, t, D) = " L(CL, V1, Q, V2, σ |yi, ti, D)
=

1

√2πσ

∗e

4

$%

6
%
8(9:,;%,<,; ,=,>)
∗ 747
56

?(@A, BC, D, BE, F, G) = H ∗ I4JF + K ∗ I4LF … … … … … … … … … . . (C)
Where:

α=

β=

A=

1 k21 − α
∗
V1
β− α

B=

1 k21 − β
∗
V1
α− β

1
∗ Tksum − √ksum ∗ ksum − 4 ∗ k21 ∗ k10 Y
2
1
∗ Tksum + √ksum ∗ ksum − 4 ∗ k21 ∗ k10Y
2
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k10 =
k12 =
k21 =

CL
V1

Q
V1
Q
V2

ksum = k10 + k12 + k21
Hence given the pharmacokinetic parameters of melphalan, the plasma
concentration (C) at time, t, after an intravenous infusion, D, administered at time, tD,
over a period of Tinf can be given by the function below:
If t – tD ≤ Tinf

H
`
∗ C − I4J∗(F4FG)
G
J
@(F) =
∗_
Z[\] _ K
+ ∗ C − I4L∗(F4FG)
^ L

c
b … … … . (Ed)
b
a

If not,
@(F) =

G

Z[\]

∗e

H
J

+

∗ C − I4J∗Z[\] ∗ I4J∗(F4FG4Z[\])

∗ C − I4L∗Z[\] ∗ I4L∗(F4FG4Z[\])
L

K

f …….(2b)

The function describing the two compartment or biphasic disposition of melphalan
is presented by the differential equations below:

dA1
= A2 ∗ k21 − A1 ∗ k12 − A1 ∗ k10 … … … … … … . . (3)
dt
12

dA2
= A1 ∗ k12 − A2 ∗ k21 … … … … … … … … … … … . . (4)
dt
2.2.3

The Bayes Rule

For Bayesian approaches, a prior is required for the computation of a posterior
distribution in accordance with the Bayes Rule (equation 5). The Bayes rule is the basis
for inference about the Bayesian population PK parameters (!: CL, V1, Q and V2 ) given

the data (y) and prior knowledge about model parameters (p((!)). The parameters are
viewed as random variables with probability distributions that naturally permit the
characterization of the uncertainty around them.
j(k|?) =

j(k) ∗ j(?|k)
∝ j(k) ∗ j(?|k) … … … … … … … …. (m)
j(?)

Where:
•
•
•

2.2.4

(!| ) is the posterior distribution of the parameter given the data;
(!) is the prior distribution of the parameters;

( |!) is the likelihood function expressed by equation (1).

The Prior distribution

The prior in Bayesian statistics represents our prior beliefs or knowledge about
a parameter. Priors can be informative, weakly informative or uninformative.
Informative prior strongly represents information that prevents the data alone from
influencing the posterior distribution. Uninformative prior on the other hand allows the
data alone to influence the posterior distribution because it lacks information. Weakly
13

informative priors contain some information about the parameter, but allows the data to
significantly influence the posterior distribution. In this work both informative priors,
parameters from non-Bayesian estimation, and weakly informative priors were used.

Normal priors for the mean of CL, Q, V1, and V2 were used. Cauchy priors were
used as weakly informative priors for the omega and sigma parameters. The LKJ priors
were used on the rho parameters. The omega parameters are the variances (diagonals)
of the variance-covariance matrix of the etas on CL, Q, V1 and V2, whereas the rho
parameters are the off-diagonal covariance. The sigma parameters are the variances of
the residual errors. The LKJ is the Cholesky LKJ correlation distribution, and is
implemented in Stan to model a covariance matrix of a multivariate normal distribution
(Sorensen and Vasishth, 2015).

2.2.5

The posterior distribution

The posterior distribution as shown in equation (5) summarizes our current state
of knowledge about a parameter after prior information and data (likelihood) (Gelman,
2002). Hence with prior information about melphalan PK parameters, and plasma
concentration data, we are able to generate the marginal distribution for each of the PK
parameters; CL, Q, V1 and V2.
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2.2.6

Posterior predictive distribution

New data (ynew) can be predicted from the posterior distribution using the
posterior predictive distribution expressed by equation (6). The predicted data is then
compared with the observed data to determine the accuracy and adequacy of the model.
(

2.2.7

nop |

)= q (

nop |!)

∗ (!| )r! … … … … … … … . . (6)

Estimation methods

Estimation methods are used to determine the parameters of a model. In
frequentist Statistics, the maximum likelihood is one of the commonly used estimation
methods. It finds a set of parameters that maximizes a likelihood function or minimizes
the negative log-likelihood of that function. In population pharmacokinetics, the
calculation of the likelihood is complex since the random effects have to be integrated
out. To circumvent this difficulty, population pharmacokinetic modeling packages
implement methods that approximate the true likelihood with another simplified
function (Mould and Upton, 2013). Some of this approximation techniques include the
first order-method (FO), and the first-order conditional estimation (FOCE) methods
(Bauer, 2019). In this work, the non-Bayesian estimation was done in NONMEM using
the FOCE method.

Bayesian techniques on the other hand are based on Markov Chain Monte Carlo
(MCMC) simulation, which overcomes the complex integration processes involved in
estimating population pharmacokinetic model parameters. Bayesian techniques
15

therefore do not approximate marginal distribution of the parameters, but gives a sample
distribution of probable population parameters with mean similar to the maximum
likelihood values (Bauer, 2019).

2.2.8

The Markov Chain Monte Carlo Simulation (MCMC)

Markov chain simulation or MCMC is based on sequential random sampling of
parameter values from an approximate distributions, and the corrections applied to those
draws help to better approximate the posterior distribution (Gelman et al., 2013). Any
aspect of the posterior distribution may be approximated exactly with a large number of
Monte Carlo samples (Hoff, 2009). To generate MCMC samples with minimal
autocorrelation, one needs a large sample draw with the appropriate thinning parameter.
Samples drawn during the warm-up phase, i.e. before the convergence of the Markov
chains, are discarded.

2.2.9

Algorithms for MCMC

Algorithms used to implement MCMC include Gibbs sampling (GS),
Metropolis-Hastings (MH), and the Hamiltonian Monte Carlo (HMC) simulation. Gibbs
sampling generates draws for the posterior distribution by sampling from the univariate
full conditional distributions.
θ% ~ p(θ% | θ 4% , θv4% , … … . θ04% , y )
θ ~ p(θ | θ% , θv4% , … … . θ04% , y )
θn ~ p(θn | θ% , θ , … … . θn4% , y )
16

The Metropolis Hastings algorithm is a general multipurpose MCMC algorithm
which requires a conditional proposal density which is easy to sample from. The HMC
algorithm is sensitive to two important parameters, step size (ϵ), and the number of steps
(L), which when properly tuned, avoids the random walk behavior and sensitivity to
correlated parameters by taking a series of steps informed by first-order gradient
information (Neal, 2011, Hoffman and Gelman, 2014). This allows the Markov chain
to converge to high dimensional target distribution quicker than the Gibbs and
Metropolis sampling (Hoffman and Gelman, 2014).

The NUTS (No-U-Turn Sampler) is an extension of the HMC algorithm. It
eliminates the need to tune the number of steps (L). In effect, an empirical NUTS will
perform as efficiently as a properly tuned HMC without requiring user tuning (Hoffman
and Gelman, 2014). The NUTS algorithm has been implemented in Stan, and has been
showing promise to estimating population pharmacokinetic and pharmacodynamic
models. Examples can be found on the website of Metrum Institute®
(https://www.metrumrg.com/course/brief-introduction-bayesian-modeling-usingstan/). In this work, Stan was used for the Bayesian part of the analysis.

2.2.10 Standard Normal Deviate and the Standard Normal Distribution

The standard normal deviate (SND) is derived from the normal distribution .
SND =

(μ − x)
σ
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The normal distribution is a bell-shaped density curve, symmetrical about its mean
(µ) with a spread determined by its standard deviation (σ).
f(x) =

1

σ√2π

∗ e4

% z4{ 6
∗(
)
5

The density is called the standard normal distribution when its mean is zero (0) and
standard deviation is one (1).
f(x) =

1

√2π

∗ e4

% 6
∗z

The standard normal distribution has wide application in science. It has been used
in reporting analytical results and to guide decision making. For instance, data are
standardized by subtracting the mean (x) from a reference (µ), and dividing this
difference by the standard deviation (σ) to construct control charts (Amin, 2001). The
control charts are then used to guide the acceptance and rejection of analytical or
manufacturing batches.
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CHAPTER 3

3

3.1

METHODOLOGY

Overview of methodology

The method used in this study is outlined in Figure 3. This included literature
search for melphalan PK models, simulation of the published PK models, evaluation
and selection of the PK models, creation of composite melphalan PK dataset, and the
creation of melphalan composite PK model.

Figure 3. Outline for developing a composite pharmacokinetic model. mSND, modified
standard normal deviate.
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3.2

Literature search for melphalan PK models

Six papers describing 7 melphalan Pop PK models were selected for analyses from
PubMed. These six papers (Nath et al., 2010, Nath et al., 2007, Mizuno et al., 2018,
Kuhne et al., 2008, Cho et al., 2018, Mougenot et al., 2004, Cho et al., 2017) are the
only available published articles that describe melphalan Pop PK. They have been
summarized in Table 1. The EVOMELA PK reported in the Clinical Pharmacology
NDA Review packet (Nov, 2015) was used as the reference model.

3.3

Design and Simulations

After selecting the melphalan models, each of them was simulated using their
respective published pharmacokinetic parameters. The design of the simulation was the
same for each model with respect to virtual subjects, covariate distribution, dose and
mode of administration of melphalan. A total of 1000 virtual subjects were simulated.
Primary covariates, i.e. the covariates that can be measured directly, were simulated
using the normal distribution:
Primary Covariate ~N (μ, σ)
The mean (u) and standard deviation (sd) used for simulating the covariates are
presented in Table 1.
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Table 1. Summary of demographic and study-related characteristics of literature used
in this study.
Model
Reference

1 and 2
C E Nath et
al 2010 (a/b)

3
C E Nath
et al 2007

4
Mizuno
et al 2018

5
Kuhne et
al 2008

6
Cho et
al 2017

7
Mougenot
et al 2004

Demography
Number of
subjects
Gender (M/F)
Age (yrs)
Height (cm)

100

59

15

84

146

64

59 / 41
36-73
147-185

38 /21
0.3 - 18
92 -137

11-Apr
48-74
-

53 / 31
37-77
155-188

90 / 56
35-72
-

22 /42
19-80
152 - 185

BSA

1.3-2.6

0.60 - 1

1.5 – 2.51

-

1.37 – 2.21

Multiple
myeloma
patients
undergoing
ASCT

Malignant
disease
children
undergoin
g
autologou
s and
allogenic
BMT

Multiple
myeloma
patients
undergoin
g HSCT

Multiple
myeloma,
nonHodgkin’s
lymphom
a, rare
tumors

Multiple
myelom
a
patients
admitte
d for
HSCT

Advanced
malignancie
s

BWT (kg)

42 – 132

13.5 –
28.1

51.2134.8

48-130

-

35 - 102

FFM

34.4-80.5

-

-

-

31.3 –
81.9

-

HCT

20-45

-

-

-

-

CrCL (ml/min)

29-234

-

35 - 164

11.9 –
179.8

30 - 195

-

86 - 139

-

-

-

-

Total

Total

Total

Total

Total

IV
15 min
140 or
180
mg/m2

IV
20 min
140 or
180
mg/m2

IV
20-30 min

IV
140 or
200
mg/m2

IV
24 hr

2CMT

2CMT

2CMT

Study
Population

Population
characteristics

Model
Covariates

GFR(ml/min
1.73m2)
Pharmacokineti
cs

Dose:
Infusion rate

Total/Unboun
d
IV
15-95 min

Dose Range

192 mg/m2

Fraction analyzed

Structure of PK
model

2CMT

21

10-200
mg/m2

2CMT

20 to 30
mg/m2
2CMT

Table 2. List of covariates used in the simulations.
Variable

Unit

Mean

Standard deviation

Weight (WT)

Kg

70

14

Age

years

60

12

Height (HT)

cm

170

34

Serum Creatinine (SCR)

mg/dl

1.1

0.22

Hematocrit (HCT)

%

34

6.8

The derived covariates were calculated from the primary covariates using the
equations below:
BMI =

WT
(HT 0 …† /100)

BSA = 0.024265 ∗ HT ‰.vŠ‹Œ ∗ WT ‰.•vŽ•
CrCl‘’“o =

CrCl˜™†š›™ =
FFMžš›™ =

FFM˜™†š›™ =

(140 − AGE) ∗ WT
(72 ∗ SCR)

0.85 ∗ (140 − AGE) ∗ WT
(72 ∗ SCR)

9.27 ∗ 1000 ∗ WT
6.68 ∗ 1000 + 216 ∗ BMI

9.27 ∗ 1000 ∗ WT
8.78 ∗ 1000 + 244 ∗ BMI
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The proportion of female to male virtual subjects was 2:3. Using a 30 minutes IV
infusion of 140 mg/m2, each model was simulated using the respective published
pharmacokinetic parameters.

3.3.1

Calculation of Exposure measures

The exposure measures, AUCinf and Cmax, were determined using NCA
implemented in PKNCA R package. The AUC was estimated using the trapezoidal rule
(Gabrielsson and Weiner, 2012) and the Cmax corresponded with the highest
concentration after IV infusion.

3.3.2

Calculation of the modified standard normal deviates (mSND)

The standard normal variate was calculated as follows:
1. Compute the average of each exposure measure.
μ

¡9 0¢

=

AUCinf% + AUCinf + ⋯ + AUCinf0
n

μ9†šz =

Cmax% + Cmax + ⋯ + Cmaxn
n

2. Compute the standard deviation of each exposure measure.
σ

¡9 0¢

= ¥

∑0$%(AUCinf − μ
n−1
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¡9 0¢ )

∑0 (Cmax − μ9†šz )
σ9†šz = ¥ $%
n−1

3. Compute the modified standard normal deviate of each ith model.
AUC SND =

(μ

Cmax SND =

¡9 0¢

σ

− AUCinf )
¡9 0¢

(μ9†šz − Cmax )
σ…†šz

4. Plot each of the models for a visual presentation of their deviates Figure 1.

3.4

Selection of melphalan pharmacokinetic models

A criterion of 0 – 3 mSND was used for model selection based on its ability to
discriminate between models which were developed using different PK data and
different model structure. The models within 0 -3 mSND were selected for repurposing,
and subsequently used to generate a composite dataset for the development of the
composite PK model.
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3.5

Development of the Composite Pharmacokinetic Model

3.5.1

Non-Bayesian approach (FOCE-I)

The composite dataset was used to develop a composite PK model. The composite
dataset consisted of 100 virtual subjects. A two compartmental pharmacokinetic model
was developed in NONMEM using First-order conditional estimation method (FOCE)
with interaction. FOCE-I is an approximation of the maximum likelihood estimation
method. The parameters estimated included CL, Q, V1 and V2. Inter-individual
variability (IIV) or etas (η) associated with each of the parameters were estimated. The
residual error variability or sigma (σ) was also estimated. The final model was evaluated
using the goodness of fit (GoF) plots (dataset versus predictions, and residuals).

3.5.2

Bayesian Method

The Bayesian methodology was implemented in Stan using the NUTS MCMC
algorithm to develop a two compartmental model. The model is expressed by equations
(2a & b). Both weakly informative priors and informative priors of the fixed effects,
CL, Q, V1, and V2 were examined during runs 1 and 2 respectively (Table 3). All other
priors were weakly informative.
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Table 3. Priors used for the Bayesian model development.
Parameter
CL
Q
V1
V2
omega
rho
sigma

Run 1
normal(0, 25)
normal(0, 50)
normal(0, 10)
normal(0, 20)
cauchy(0, 1)
*lkj_corr(1)
cauchy(0, 1)

Run 2
normal(27.7, 25)
normal(19, 50)
normal(27.4, 10)
normal(15.7, 20)
cauchy(0, 1)
lkj_corr(1)
cauchy(0, 1)

The posterior distribution were expressed as:
Log(φ) ~ multi_normal(log(φ), Omega)
C ~ lognormal(log(y(CL, V1, Q, V2, t, D)), sigma)
The conditions for each run were: number of chains = 4; burn-in samples = 500,
post-burn-in samples = 1000; number of iterations = 1500; and thinning number= 1.
The convergence of the Markov chains were assessed by examining the traceplots
for stationarity and mixing of the four chains. A straight horizontal fuzzy caterpillar,
rather than a wiggly snake, is an indication of adequate mixing and hence convergence.
Also the potential scale reduction statistics (Rhat) was examined. The Rhat compares
the between and within variances of the chains (Brooks and Gelman, 1998). An Rhat of
1 is an indication that all chains were in equilibrium and converged to a common
distribution. Similar to the non-Bayesian approach, the composite dataset was compared
with predictions from the model to evaluate the adequacy of the predictions.
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CHAPTER 4

4

4.1

FINDINGS

Description of published melphalan Pharmacokinetic models

From the 6 published papers, 7 Pop PK models of melphalan were selected, and
simulated (Figure 4). The 7 models represented melphalan PK in about 450 patients
with multiple myeloma (MM) and malignancies, who were undergoing allogenic or
autologous stem cell transplantation.

Figure 4. Individual plots of simulated plasma concentration of melphalan: after 30
minutes IV infusion of 140 mg/m2 of melphalan. M1: Nath et al. 2010a ; M2: Nath et
al. 2010b; M3: Nath et al. 2007; M4: Cho et al. 2018; M5: Kuhne et al. 2007; M6:
Mizuno et al. 2018; M7: Mougenot et al. 2004.
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Melphalan doses of 20 – 200 mg/m2 were administered in the original studies
(Table 1). The data used to develop the original published models were from total
melphalan plasma concentration, except M2 (Nath et al., 2010), which was developed
using unbound concentration. Additionally, the original studies were conducted in adult
patients except M3 (Nath et al., 2007), which was conducted in pediatric patients.
The PK models were all described as two compartment models except M7
(Mougenot et al., 2004), which was described as a one-compartmental model. At least,
body weight or other measures of body weight was used as a covariate on a parameter
in all the models used in this study. Other covariates found included creatinine clearance
(CrCl), glomerular filtration rate (GFR), and hematocrit (HCT).

4.2

The modified standard normal deviate (mSND) provided a criterion for
discriminating published melphalan PK models.

The modified standard normal deviate (mSND) used in this work provided an
approach for discriminating the predictive performance of the published PK models.
Models with exposure measures within a mSND of 0-3 were considered to be predictive
of the 140 mg/m2 melphalan dose. Predictions of AUCinf and Cmax were all within 03 SND, except M2 (Nath et al. 2010b) and M7 (Mougenot et al. 2004) which deviated
by more than 3 units (Table 4 & Figure 5). This suggests three important things
regarding the published melphalan Pop PK models.
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Table 4. Summary of the modified standard normal deviates (mSND) of 7 published
melphalan PK models.
Model
Number
M1
M2
M3
M4
M5
M6
M7

Published
Paper
Nath et al.
2010a
Nath et al.
2010b
Nath et al.
2007
Cho et al. 2017
Kuhne et al.
2007
Mizuno et al.
2018
Mougenot et
al. 2004

Cmax
(mg/L)
9.1

SND of
Cmax
2.2

AUC
(mg.hr/L)
9.4

SND of
AUC
2.9

1.9

8.4

2.0

6.5

9.5

2.9

8.6

1.5

7.6
7.1

0.3
0.1

8.7
7.2

1.6
0.2

7.4

0.2

6.8

0.0

4.1

2.4

2.6

5.1

Firstly, it suggests that the data used to generate melphalan PK model is an
important factor that can limit future predictions. Models based on unbound melphalan
plasma concentration may not predict total plasma concentration adequately without an
appropriate correction factor. For this reason, caution should be exercised when such
models are repurposed to predict total plasma concentrations.
Second, the structure of the Pop PK model is a source of variability in predictions.
This is consistent with the higher mSND associated with the AUCinf predicted by M7
(Mougenot et al. 2004) presented in Figure 5. In the study design of M7 (Mougenot et
al. 2004), unlike the other papers, melphalan was infused for more than 24 hours. M7
design informed a one compartment model structure, and was inadequate to predict
melphalan PK after short IV infusion like the others.
Lastly, irrespective of the covariate used to explain between-subject variability in
PK, majority of the models predicted AUCinf and Cmax within 3 mSND. This suggests
that any of those models within 0-3 mSND; M1, M3, M4, M5, and M6; could be selected
30

and repurposed based on the covariates one can afford to measure. Alternatively, a
composite model which combines all the eligible models can be developed and
repurposed rather than selecting one.

Figure 5. The modified standard normal deviates (mSND) based on AUC and Cmax.
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4.3

A 2-compartmental model adequately fit the melphalan composite data using
FOCE-I.

Using the non-Bayesian approach, a two compartmental model was developed
from composite data generated from models M1, M3, M4, M5, and M6. The goodness
of fit plots (GoF) showed adequate fit of the two compartmental model to the composite
data (Figure 6). The model parameters were: clearance (CL), 27.7 L/hr; distributional
clearance (Q), 27.4 L/hr; volume of central compartment (V1), 19 L; and volume of
peripheral compartment (V2).

Figure 6. Goodness of fit plot of the composite PK model using FOCE-I.
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Table 5. Pharmacokinetic parameters of the composite melphalan PK model using
Bayesian HMC-NUTS estimation.
Parameters based on weakly informative priors
Mean
SD
2.50% 97.50% n_eff
27.72
1.12
25.60
30.08
1836
CL
25.57
2.44
20.89
30.56
14
Q
19.08
1.03
17.13
21.17
1383
V1
15.65
1.03
13.67
17.68
1124
V2
0.005 0.0001
0.005
0.005
1402
sigma
0.41
0.03
0.36
0.47
1646
omega[1]
0.87
0.13
0.64
1.12
3
omega[2]
0.55
0.04
0.48
0.64
61
omega[3]
0.62
0.05
0.53
0.73
32
omega[4]
Parameters based on informative priors
Mean
SD
2.50% 97.50% n_eff
27.95
1.16
25.79
30.28
3821
CL
25.94
2.45
21.10
30.82
16
Q
19.42
1.08
17.36
21.63
2672
V1
15.75
1.04
13.82
17.85
2852
V2
0.005 0.0001
0.005
0.005
3809
sigma
0.41
0.03
0.36
0.47
4376
omega[1]
0.87
0.13
0.65
1.11
3
omega[2]
0.55
0.04
0.48
0.64
70
omega[3]
0.62
0.05
0.53
0.72
47
omega[4]
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Rhat
1.00
1.08
1.01
1.01
1.00
1.00
1.65
1.03
1.04
Rhat
1.00
1.07
1.01
1.01
1.00
1.00
1.65
1.02
1.03

4.4

A 2-compartmental model adequately fit the melphalan composite data using
HMC – NUTS MCMC.

Again, a two-compartmental model adequately fit the composite data when
Hamiltonian Monte Carlo No-U-Turn-Sampler MCMC was used. This Bayesian
methodology confirmed the non-Bayesian model developed using FOCE-I. Both
informative and weakly-informative priors gave similar parameter estimates (Table 5).
The traceplots and Rhat presented in the Appendix indicated successful convergence
and adequate mixing of the chain.

Table 6. Comparison of pharmacokinetic parameters of composite and reference
(Evomela NDA) melphalan models.
Parameter

Reference FOCEI

NUTS-MCMC
Weakly
Informative
Informative Prior
Prior

27.07
27.7
27.72
27.95
CL (L/hr)
23.22
27.4
25.57
25.94
Q (L/hr)
20.29
19
19.08
19.42
V1 (L)
14.61
15.7
15.65
15.75
V2 (L)
40.6
41
41
Omega 1
(%)
60.5
87
87
Omega 2
(%)
55.3
55
55
Omega 3
(%)
63.9
62
62
Omega 4
(%)
0.036
0.0132
0.005
0.005
Sigma
(mg/L)
FOCE-I, First-order conditional estimation with interaction; CL and Q are
clearance parameters, V1 and V2 are volume of distribution parameters; Omega 1, 2,
3 and 4 are the etas (inter-individual variability parameter) on CL, Q, V1 and V2
respectively.

34

4.5

The Bayesian and non-Bayesian composite PK models of melphalan agree with
the reference EVOMELA NDA model

The reference model from the EVOMELA NDA packet was compared with the
composite models developed using both Bayesian and non-Bayesian approaches. The
parameter estimates (Table 6) and the model predictions (Figure 7) agree with those
from the EVOMELA NDA packet. This confirmed that the modified standard normal
deviate was able to select models with similar predictive performance, and those models
could be combined into a composite model. Again, the agreement between the
composite model and the reference suggests that literature data can be repurposed to
develop composite PK models.

Figure 7. Comparison of predictions from melphalan composite models and reference
(EVOMELA NDA) model. The predictions of the composite and reference models are
in agreement with each other. EVOMELA NDA; Reference model; FOCE-I First-order
conditional estimation with interaction; NUTS:InPr, Bayesian composite model with
informative prior; NUTS:WKInPr, Bayesian composite model with weakly informative
prior. Shaded region is 95% confidence interval of EVOMEL NDA model.
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4.6

Potential areas of application and summary of findings

Model and parameter repurposing is common in quantitative clinical
pharmacology, especially, in the development of complex quantitative systems
pharmacology (QSP), and PBPK models. Usually, the base model and parameters are
selected from literature and modified to provide evidence to support dosing and design
of clinical trials. An example is the development of an integrated PBPK model of
calcium homeostasis and bone biology (Peterson and Riggs, 2010), where three
previously published models (Raposo et al., 2002, Lemaire et al., 2004, Bellido et al.,
2003) served as the foundation for the new one. The new model with calcium
homeostasis component (Peterson and Riggs, 2010) was then used to perform
simulations to support the adequacy of proposed dosing regimen in regulatory review
of Natpara in hypothyroidism (Khurana et al., 2019).
Similar to systems model, pharmacokinetic models of drugs may also be selected
from literature and repurposed. Marketed drugs may have several PK models available
in literature, which may be selected and repurposed to support the development of
combination therapeutic products.
In this work, our approach offered two options for repurposing melphalan PK
models (Figure 8). First, it offered us the option of choosing any of M1, M3, M4, M5,
M6 or the reference model, depending on which covariates we are able to afford.
Second, it offered us a composite model which averaged M1, M3, M4 , M5 and M6,
and may be used when we have no interest in covariates.
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Figure 8. Models to choose from for repurposing. M1: Nath et al. 2010a; M3: Nath et
al. 2007; M4: Cho et al. 2018; M5: Kuhne et al. 2007; M6: Mizuno et al. 2018; BWT,
body weight; FFM, free fat mass; HCT, hematocrit; CRCL, creatinine clearance; GFR,
glomerular filtration rate.
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5

CONCLUSION

The modified standard normal deviate provided an objective criterion for selection
of melphalan models based on the prediction of exposure after a given dose. The
approach showed that the PK data, unbound or total concentration, and model structure
were sources of variability in the predictions of exposure measures.
Additionally, this approach guided the development of a composite Pop PK model
which approximately averaged previous models. Bayesian, using informative and
weakly informative priors, gave similar parameters and predictions like the nonBayesian approach. Predictions from the composted models agreed with predictions
from reference model in EVOMELA Clinical Pharmacology NDA Review packet. This
confirms the validity of the composite model and the approach used.
It is hoped that further refinement of this approach will provide a more objective
approach for selecting PK models for repurposing. In the future, the sample size for the
SISA step can be optimized to mimic the proportion of subjects in the original studies.
Additionally, the uncertainty associated with each parameter may also be evaluated
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6

6.1

APPENDICES

Bayesian Diagnostics: pair plots (using informative priors)
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6.2

Bayesian Diagnostics: pair plots (using weakly informative priors)
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6.3

Bayesian diagnostics: traceplots (left: informative priors; right weakly
informative priors)
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6.4

Bayesian: Parameter distribution
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